Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 18
- Registration Number
- NCT00665834
- Locations
- 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada
🇨🇦Vascular Disease Prevention and Research Centre, Hotel Dieu Hospital, Kingston, Ontario, Canada
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
- Conditions
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00660764
Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 8
- Registration Number
- NCT00658463
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Dijon, Dijon, France
Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT00657527
48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
- Conditions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT00654602
IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin
- Conditions
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 442
- Registration Number
- NCT00654446
STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges
- Conditions
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5625
- Registration Number
- NCT00654537
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 940
- Registration Number
- NCT00654485
Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4875
- Registration Number
- NCT00654407
Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00654394
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.